Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 836-842, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-942965
ABSTRACT
Surgery is the main treatment for resectable esophageal squamous cell carcinoma. However, for patients with locally advanced lesions, surgery-based comprehensive treatment is the best treatment strategy. According to the results of some randomized controlled clinical studies and meta-analysis, preoperative neoadjuvant therapy is recommended to improve the survival rate of patients. Neoadjuvant therapy includes neoadjuvant chemotherapy, chemoradiotherapy, targeted therapy and immunotherapy. Great progress has been made in neoadjuvant therapy, but there are still many clinical problems that need to be solved urgently, including the efficacy and safety of neoadjuvant therapy, the choice of neoadjuvant regimen and treatment cycle, the best combination and advantages of multimodal treatment, and the selection of responders to treatment, etc. This article provides a systematic review of the latest developments and existing controversies in neoadjuvant therapy for esophageal squamous cell carcinoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Esophageal Neoplasms
/
Esophagectomy
/
Combined Modality Therapy
/
Neoadjuvant Therapy
/
Chemoradiotherapy
/
Esophageal Squamous Cell Carcinoma
Type of study:
Controlled clinical trial
/
Systematic reviews
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Gastrointestinal Surgery
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS